References of "Lancellotti, Patrizio"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailChronic ischemic mitral regurgitation
DULGHERU, Raluca Elena ULg; LANCELLOTTI, Patrizio ULg

in Applied echocardiography in coronary artery disease (in press)

Detailed reference viewed: 37 (6 ULg)
Full Text
Peer Reviewed
See detailInvited Commentary
Lancellotti, Patrizio ULg; Nchimi Longang, Alain ULg

in Annals of Thoracic Surgery (2017), 103(1), 81-82

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULg; Lancellotti, Patrizio ULg; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailQuantitative Three-Dimensional Color Flow Echocardiography of Chronic Mitral Regurgitation: New Methods, New Perspectives, New Challenges
zhou, x; vannan, m; LANCELLOTTI, Patrizio ULg

in Journal of the American Society of Echocardiography (2016), 29(10), 935-937

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailHeart Team Liege - Session Video Link
PIERARD, Luc ULg; vahanian, Alec; LANCELLOTTI, Patrizio ULg et al

Conference (2016, September)

Detailed reference viewed: 70 (1 ULg)
Peer Reviewed
See detailHeart Team Session
PIERARD, Luc ULg; LANCELLOTTI, Patrizio ULg; PETERMANS, Jean ULg et al

Conference (2016, August)

Detailed reference viewed: 23 (3 ULg)
Peer Reviewed
See detailCARDIAC ONCOLOGY
GALDERISI, Maurizio; PLANA, JC; EDVARDSEN, Thor et al

in THE EACVI TEXTBOOK OF ECHOCARDIOGRAPHY - SECOND EDITION (2016)

Detailed reference viewed: 13 (1 ULg)
Peer Reviewed
See detailHeart valve disease (mitral valve disease): mitral regurgitation
LANCELLOTTI, Patrizio ULg; DULGHERU, Raluca Elena ULg; VANNAN, M. et al

in THE EACVI TEXTBOOK OF ECHOCARDIOGRAPHY - SECOND EDITION (2016)

Detailed reference viewed: 15 (1 ULg)
Peer Reviewed
See detailHeart valve disease: (aorte valve disease): aortic regurgitation
TRIBOUILLOY, C; LANCELLOTTI, Patrizio ULg; PETERS, F. et al

in THE EACVI TEXTBOOK OF ECHOCARDIOGRAPHY - SECOND EDITION (2016)

Detailed reference viewed: 9 (2 ULg)
See detailTHE EACVI ECHOCARDIOGRAPHY TEXTBOOK - SECOND EDITION
LANCELLOTTI, Patrizio ULg; ZAMORANO; HABIB et al

Book published by Oxford University Press (2016)

Detailed reference viewed: 7 (1 ULg)
Peer Reviewed
See detailASSESSMENT OF SECONDARY MITRAL REGURGITATION
DULGHERU, Raluca Elena ULg; INCARNATE, Pierluigui; LANCELLOTTI, Patrizio ULg

in CURRENT APPROACH TO HEART FAILURE (2016)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailNormal reference values for echocardiography: a call for comparison between ethnicities.
Cosyns, Bernard; LANCELLOTTI, Patrizio ULg

in European Heart Journal - Cardiovascular Imaging (2016), 17(5), 523-4

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailEACVI appropriateness criteria for the use of cardiovascular imaging in heart failure derived from European National Imaging Societies voting.
Garbi, Madalina; Edvardsen, Thor; Bax, Jeroen et al

in European heart journal cardiovascular Imaging (2016)

This paper presents the first European appropriateness criteria for the use of cardiovascular imaging in heart failure, derived from voting of the European National Imaging Societies representatives. The ... [more ▼]

This paper presents the first European appropriateness criteria for the use of cardiovascular imaging in heart failure, derived from voting of the European National Imaging Societies representatives. The paper describes the development process and discusses the results. [less ▲]

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailMalignant Mitral Valve Prolapse: Substrates to Ventricular Remodeling and Arrhythmias.
LANCELLOTTI, Patrizio ULg; Garbi, Madalina

in Circulation: Cardiovascular Imaging (2016), 9(8), 005248

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailCalcific aortic stenosis.
Lindman, Brian R.; Clavel, Marie-Annick; Mathieu, Patrick et al

in Nature Reviews. Disease Primers (2016), 2

Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed countries. It is characterized by progressive fibro-calcific remodelling and thickening of the aortic valve leaflets ... [more ▼]

Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed countries. It is characterized by progressive fibro-calcific remodelling and thickening of the aortic valve leaflets that, over years, evolve to cause severe obstruction to cardiac outflow. In developed countries, AS is the third-most frequent cardiovascular disease after coronary artery disease and systemic arterial hypertension, with a prevalence of 0.4% in the general population and 1.7% in the population >65 years old. Congenital abnormality (bicuspid valve) and older age are powerful risk factors for calcific AS. Metabolic syndrome and an elevated plasma level of lipoprotein(a) have also been associated with increased risk of calcific AS. The pathobiology of calcific AS is complex and involves genetic factors, lipoprotein deposition and oxidation, chronic inflammation, osteoblastic transition of cardiac valve interstitial cells and active leaflet calcification. Although no pharmacotherapy has proved to be effective in reducing the progression of AS, promising therapeutic targets include lipoprotein(a), the renin-angiotensin system, receptor activator of NF-kappaB ligand (RANKL; also known as TNFSF11) and ectonucleotidases. Currently, aortic valve replacement (AVR) remains the only effective treatment for severe AS. The diagnosis and staging of AS are based on the assessment of stenosis severity and left ventricular systolic function by Doppler echocardiography, and the presence of symptoms. The introduction of transcatheter AVR in the past decade has been a transformative therapeutic innovation for patients at high or prohibitive risk for surgical valve replacement, and this new technology might extend to lower-risk patients in the near future. [less ▲]

Detailed reference viewed: 22 (2 ULg)